Categories: NewsPharmaceutical

Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Company to host an investor conference call and webcast at 4:30pm ET on that day

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, today announced that the Company will release financial results for the third quarter ended September 30, 2022 on Thursday, November 10, 2022, after the markets close. Following the release, Eyenovia management will host a conference call to review the financial and operating results.

The conference call is scheduled to begin at 4:30pm ET on Thursday, November 10, 2022. Participants should dial 1-866-575-6539 (domestic) or 1-929-477-0448 (international) with the conference code 1600616. A live webcast of the conference call will also be available on the investor relations page of the Company’s corporate website at www.eyenovia.com.

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia, and myopia progression. For more information, visit www.eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com

Staff

Recent Posts

Former Nike VP & GM Bert Hoyt Joins dBio to Drive Next-Gen Sports & Health Tech as Board Advisor

LUXEMBOURG, April 23, 2025 /PRNewswire/ -- Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), a leading…

51 minutes ago

Labroots Open-Access Scientific Virtual Event Lineup: Spring 2025

YORBA LINDA, Calif., April 23, 2025 /PRNewswire/ -- Labroots, the leading scientific social networking website…

51 minutes ago

Aleutian Capital Group Advises 1984 System, Inc. dba American Data in Its Sale to Valsoft Corporation

NEW YORK--(BUSINESS WIRE)--Aleutian Capital Group (“Aleutian”) is pleased to announce Valsoft Corporation (“Valsoft”) successful acquisition…

4 hours ago

InsideTracker Announces Terra, Taking AI-Driven Real-Time Health Coaching and Recommendations to a New Level.

The new AI agent integrates the benefits of an LLM and KRR to deliver private,…

4 hours ago

RAAPID Joins Microsoft for Startups Pegasus Program with Transactable Marketplace Offer

Achievement is set to accelerate enterprise AI solutions through Microsoft's startup acceleration program LOUISVILLE, Ky.--(BUSINESS…

7 hours ago

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

7 hours ago